SPOTLIGHT -
Future Outlook for Alzheimer’s Disease
Drs Atri, Cohen, Sabbagh and McDade share their enthusiasm and optimism about the future outlook for Alzheimer’s disease.
Prevention Trials in Alzheimer’s Disease
Dr Eric McDade shares information on different types of prevention trials to manage Alzheimer’s disease.
Data from Other Emerging Alzheimer’s Disease Treatment Options from CTAD 2022
Expert neurologists share information on drugs with different mechanisms of actions that are being evaluated in clinical trials for Alzheimer’s disease.
Other Anti-Amyloid Antibody Agents for Treatment of Alzheimer’s Disease
Drs McDade and Atri discuss differences and similarities between other ongoing anti-amyloid antibody trials in Alzheimer’s disease.
Lecanemab for Treatment of Alzheimer’s Disease
Drs Cohen, Atri, and Sabbagh share data on lecanemab, an anti-amyloid beta antibody, that was presented at CTAD 2022.
Management of Amyloid Related Imaging Abnormalities (ARIA) for Alzheimer’s Disease
Dr Atri comments on observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shares his thoughts on management of ARIA.
Aducanumab for Treatment of Alzheimer’s Disease
Dr Atri discusses aducanumab, first FDA approved anti-amyloid-beta antibody for treatment of Alzheimer’s disease.
Treatment Pipeline for Alzheimer’s Disease
Drs McDade, Atri, Cohen, and Sabbagh discuss candidates drugs and various mechanisms of actions that are currently under evaluation for Alzheimer’s disease.
Management of Neuropsychiatric symptoms of Alzheimer’s Disease
Dr Atri emphasizes importance of managing neuropsychiatric symptoms in patients with Alzheimer’s disease and drugs under development.
Current Treatment Options for Alzheimer’s Disease
Dr Cohen shares current treatment options for Alzheimer’s disease and how she manages these patients in her practice.
Considerations for Management of Alzheimer’s Disease
Dr Atri discusses considerations and suggestions for caring for patients with Alzheimer’s disease.
Factors Contributing to Clinical Trial Failures in Alzheimer’s Disease
Dr. Cohen shares factors that may have contributed to the high failure rate of Alzheimer’s disease clinical trials thus far.
Use of ATN Classification for Alzheimer’s Disease in Clinical Practices
Drs McDade and Cohen discuss ATN (amyloid, tau, neurodegeneration) classification and its use in clinical practice to manage Alzheimer’s disease.
Importance of Primary Care Physicians in Diagnosis of Alzheimer’s Disease
Dr Cohen emphasizes the importance of engagement of primary care physicians in identification of Alzheimer’s disease symptoms and pathology.
Diagnostic Pathway for Alzheimer’s Disease
Dr. Atri discusses his approach to diagnosis and Dr. McDade updates on the use of tau-PET for diagnosis of Alzheimer’s disease.
Ongoing Research and Use of Biomarkers and Imaging in Alzheimer’s Disease
Dr Atri shares his excitement about ongoing research and the use of biomarkers and imaging for management Alzheimer’s disease.
Genetic and Structural Heterogeneity in Alzheimer’s Disease
Drs McDade and Sabbagh discuss heterogeneity in Alzheimer’s disease and structural polymorphism and genetic mosaicism seen in patients.
Biomarkers and Challenges to the Use of Biomarkers in Alzheimer’s Disease
Drs Atri and Cohen discuss biomarkers for Alzheimer’s disease and the challenges in their use in routine practice.
Current Understanding of Alzheimer’s Disease Pathology
Four Alzheimer’s disease expert discuss our current understanding of Alzheimer’s disease pathology and the presence of amyloid and tau pathologies in patients.
